What to expect from HER-2 directed therapies in advanced gastric cancer? | Zendy

Faysal Dane | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

What to expect from HER-2 directed therapies in advanced gastric cancer?

Author(s) -

Faysal Dane

Publication year - 2015

Publication title -

marmara medical journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.112

H-Index - 11

ISSN - 1309-9469

DOI - 10.5472/mmj.87204

Subject(s) - medicine , cancer , intensive care medicine

Gastric cancer is the second most common cause of cancer related death worldwide. Over 20% of the advanced gastric cancer are considered to be HER-2 positive. Studies investigating the prognosis of HER-2 positive advanced gastric cancer revealed conflicting results. Trastuzumab, a monoclonal antibody against HER-2, has shown a significant clinical activity in HER-2 positive gastric cancer patients. In this review, I will briefly summarize the clinical studies of anti-HER-2 therapies performed in HER-2 positive gastric carcinoma. Keywords: Gastric cancer, HER-2/neu, Targeted therapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research